Evaluation of Defined Daily Dose, percentage of British National Formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization

Saudi Pharmaceutical Journal

Volumn 22, Issue 2, 2014, Pages 127-132

  Sweileh, Waleed M ^a   Odeh, Jihad Bani ^a   Shraim, Naser Y ^a   Zyoud, Sa'ed H ^a   Sawalha, Ansam F ^a   Al Jabi, Samah W ^a  

^a AN NAJAH NATIONAL UNIVERSITY   (Palestine)

Author keywords

Antipsychotics; Chlorpromazine equivalents; Defined Daily Doses; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CORRELATION COEFFICIENT; DRUG FORMULARY; DRUG UTILIZATION; FEMALE; HEALTH CARE; HUMAN; LINEAR REGRESSION ANALYSIS; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NOMENCLATURE; OUTPATIENT; SCHIZOPHRENIA;

EID: 84895507120     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2013.03.003     Document Type: Article

References (23)

1. Alonso J., Angermeyer M.C., Bernert S., Bruffaerts R., Brugha T.S., Bryson H., de Girolamo G., Graaf R., Demyttenaere K., Gasquet I., Haro J.M., Katz S.J., Kessler R.C., Kovess V., Lepine J.P., Ormel J., Polidori G., Russo L.J., Vilagut G., Almansa J., Arbabzadeh-Bouchez S., Autonell J., Bernal M., Buist-Bouwman M.A., Codony M., Domingo-Salvany A., Ferrer M., Joo S.S, Martinez-Alonso M.C., Matschinger H., Mazzi F., Morgan Z., Morosini P., Palacin C., Romera B., Taub N., Vollebergh W.A. Psychotropic drug utilization in Europe: results from the European study of the epidemiology of mental disorders project. Acta Psychiatr. Scand. 2004, 1:55-64.
2. Bezchlibnyk-Butler K.Z., Jeffries J.J. Clinical Handbook of Psychotropic Drugs 2007, Hogrefe & Huber, Seattle. 17th rev. ed.
3. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2009, 36:71-93.
4. Davis J.M. Comparative doses and costs of antipsychotic medication. Arch. Gen. Psychiatry 1976, 33:858-861.
5. Dewan M.J., Koss M. The clinical impact of reported variance in potency of antipsychotic agents. Acta Psychiatr. Scand. 1995, 91:229-232.
6. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. Am. J. Psychiatry 2010, 167:686-693.
7. British National Formulary 2010, Joint Formulary Committee, British Medical Association, Pharmaceutical Society of Great Britain, BMJ Group & Pharmaceutical Society, London, UK.
8. Dipiro Joseph, Talbert Robert L., Yee Gary C., Matzke Gary R., Wells Barbara G., Posey L.M. Pharmacotherapy, a Pathophysiologic Approach 2011, The McGraw - Hill Companie. 8th ed.
9. McEvoy J.P., Hogarty G.E., Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry 1991, 48:739-745.
10. NICE, 2011. National collaborating centre for mental health. National institute for health and clinical excellence clinical guideline 82. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update). <> (accessed 23.01.11). http://www.nice.org.uk/CG82.
11. Nose M., Tansella M., Thornicroft G., Schene A., Becker T., Veronese A., Leese M., Koeter M., Angermeyer M., Barbui C. Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages?. Int. Clin. Psychopharmacol. 2008, 23:287-290.
12. Peralta V., Cuesta M.J., Caro F., Martinez-Larrea A. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices. Acta Psychiatr. Scand. 1994, 90:354-357.
13. Piparva K.G., Parmar D.M., Singh A.P., Gajera M.V., Trivedi H.R. Drug utilization study of psychotropic drugs in outdoor patients in a teaching hospital. Indian J. Psychol. Med. 2011, 33:54-58.
14. Rey M.J., Schulz P., Costa C., Dick P., Tissot R. Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics. Int. Clin. Psychopharmacol. 1989, 4:95-104.
15. Rijcken C.A., Monster T.B., Brouwers J.R., de Jong-van den Berg L.T. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses?. J. Clin. Psychopharmacol. 2003, 23:657-659.
16. Stone C.K., Garve D.L., Griffith J., Hirschowitz J., Bennett J. Further evidence of a dose-response threshold for haloperidol in psychosis. Am. J. Psychiatry 1995, 152:1210-1212.
17. Warner J., Slade R., Barnes T.R. Change in neuroleptic prescribing practice. Psychiatr. Bull. 1995, 19:237-239.
18. WHO, 2010. Guideline for ATC classification and DDD assignment 2010. WHO collaborating centre for drug statistics methodology. Oslo 2009.
19. WHO, <>. http://www.who.int/mental_health/management/schizophrenia/en/.
20. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64:663-667.
21. Xiang Y.T., Weng Y.Z., Leung C.M., Tang W.K., Ungvari G.S., Gerevich J. Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:756-760.
22. Xiang Y.T., Weng Y.Z., Leung C.M., Tang W.K., Ungvari G.S. Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China. Int. J. Clin. Pharmacol. Ther. 2008, 46:245-251.
23. Yorston G. Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics. Psychiatr. Bull. 2000, 24:130-132.